CommercialAdministrativeMedium impact
08.01.40h, Lanreotide (Somatuline® Depot)
Independence Blue Cross·Endocrinology, Gastroenterology, Oncology·Pharmacy
Effective date
Nov 17, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.01.40h for Lanreotide (Somatuline® Depot) has been updated effective 11/17/2025 with changes to medical necessity criteria and medical coding requirements. The billing team must review updated coverage criteria and ensure claims are submitted with correct coding and documentation to avoid denials.
Action Required
By 11/17/2025: Billing team must obtain and review the complete updated policy text for Lanreotide (Somatuline® Depot) from https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=11&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-40h. Identify specific changes to medical necessity criteria and coding requirements. Update billing software, prior authorization templates, and provider documentation guidelines accordingly. Communicate changes to providers and clinical staff. Verify all Lanreotide claims submitted after 11/17/2025 comply with new criteria to prevent denials.